Vidaza azacitidine regulatory update

The European Commission approved a label expansion for Vidaza azacitidine from Celgene to include treatment of patients ages >=65 who are not eligible for hematopoietic stem cell transplantation (HSCT) with acute myelogenous leukemia (AML) with >30% bone marrow blasts. Vidaza was previously approved to treat patients who are not eligible for HSCT with AML with 20-30% blasts and multi-lineage dysplasia. ...